Daxor (DXR)
(Delayed Data from NSDQ)
$9.00 USD
+0.30 (3.45%)
Updated Aug 15, 2024 09:55 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
DXR 9.00 +0.30(3.45%)
Will DXR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DXR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for DXR
Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer
Daxor awarded $1.9M contract by the U.S. Air Force
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor expands blood volume analysis in three new facilities
Daxor awarded $550K matching-fund extension from U.S. DHA